Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

1. Alendronate

Alendronate Top results for alendronate - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alendronate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Background Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. Methods We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open (...) -label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw

NEJM2017

3. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.

Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Importance: Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids. Objective: To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects. Design, Setting (...) , and Participants: Retrospective cohort study using a national database (N = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred

JAMA2017

4. Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday

Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday UTCAT3257, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday Clinical Question In patients being treated with oral (...) alendronate and wanting a dental implant, does taking a drug holiday decrease the likelihood of developing osteonecrosis of the jaw? Clinical Bottom Line Patients being treated with oral alendronate and in need of a dental implant should have their dentist discuss the discontinuation of their oral bisphosphonate with their prescribing physician before continuing with dentoalveolar surgical treatment. The amount of risk reduction seems to necessitate further investigation and therefore, one cannot provide

UTHSCSA Dental School CAT Library2017

5. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty

Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty 28318867 2017 03 20 2017 03 20 1532-8406 2017 Feb 27 The Journal of arthroplasty J Arthroplasty Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty. S0883-5403(17)30154-7 10.1016/j.arth.2017.02.036 Bone mineral density (BMD) loss around femoral implants, particularly in the proximal femur, is a common outcome after total hip arthroplasty (...) . Previous studies reported the prevention of postsurgical decrease in BMD with the use of osteoporosis drug therapy. This randomized study evaluated the efficacy of alendronate and alfacalcidol for preserving BMD over a long-term follow-up. Sixty consecutive patients with hip osteoarthritis who had undergone primary cementless total hip arthroplasty were randomly assigned to an alendronate (n = 20), alfacalcidol (n = 18), or control (n = 22) group. Periprosthetic BMD was measured using dual-energy X-ray

EvidenceUpdates2017

7. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. OBJECTIVES: To determine the skeletal safety and efficacy of long term (≥10 years) alendronate use in patients with osteoporosis. DESIGN: Open register based cohort study containing two nested case control studies. SETTING: Nationwide study of population of Denmark. PARTICIPANTS: 61 990 men and women aged 50-94 at the start of treatment, who (...) had not previously taken alendronate, 1996-2007. INTERVENTIONS: Treatment with alendronate. MAIN OUTCOME MEASURES: Incident fracture of the subtrochanteric femur or femoral shaft (ST/FS) or the hip. Non-fracture controls from the cohort were matched to fracture cases by sex, year of birth, and year of initiation of alendronate treatment. Conditional logistic regression models were fitted to calculate odds ratios with and without adjustment for comorbidity and comedications. Sensitivity analyses

BMJ2016

8. Alendronic acid (Binosto) - Treatment of postmenopausal osteoporosis

Alendronic acid (Binosto) - Treatment of postmenopausal osteoporosis Published 11 April 2016 Product Update: alendronic acid 70mg effervescent tablet (Binosto ® ) SMC No.(1137/16) Internis Pharmaceuticals Ltd 04 March 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) alendronic acid effervescent tablets (Binosto ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of postmenopausal osteoporosis. SMC restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice. Alendronic acid 70mg effervescent tablets have demonstrated bioequivalence to alendronic acid 70mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets

Scottish Medicines Consortium2016

9. Alendronate

Alendronate USE OF ALENDRONIC ACID IN PREGNANCY 0344 892 0909 USE OF ALENDRONIC ACID IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Alendronic acid is a bisphosphonate licensed in adults for the treatment of postmenopausal osteoporosis (...) and for the prophylaxis of glucocorticoid-induced osteoporosis. As alendronic acid is incorporated into bone, the terminal half-life is long (up to 10 years). Fetal exposure could therefore occur in pregnant women with a history of alendronic acid use prior to conception. Animal studies have demonstrated that alendronic acid can be absorbed into the fetal skeleton and affect offspring incisor eruption. The available human exposure data are highly limited, consisting of a single prospective cohort study and case

UK Teratology Information Service2014

10. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening

NHS Economic Evaluation Database.2013

11. Oral ulcers, a little known adverse effect of alendronate: review of the literature

Oral ulcers, a little known adverse effect of alendronate: review of the literature Oral ulcers, a little known adverse effect of alendronate: review of the literature Oral ulcers, a little known adverse effect of alendronate: review of the literature Kharazmi M, Sjoqvist K, Warfvinge G CRD summary The review concluded that alendronate was associated with development of oral ulcers as healing occurred when the drug was either withdrawn or administered correctly. Due to very limited evidence (...) and substantial risk of bias in the review process, the authors' conclusions cannot be considered reliable. Authors' objectives To review the published data on the relationship of mucosal ulcers in the oral cavity with the use of alendronate. Searching PubMed was searched for relevant published studies from 1966 to August 2010. There were no language restrictions. Limited search terms were reported. Reference lists of selected reports were searched. Study selection Studies that reported ulceration of the oral

DARE.2012

12. Binosto (alendronate sodium) effervescent tablets

Binosto (alendronate sodium) effervescent tablets Drug Approval Package: Binost (alendronate sodium) NDA #202344 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Binosto (alendronate sodium) effervescent tablets, 70 mg Company: EffRx Pharmaceuticals SA Application No.: 202344 Approval Date: 03/12/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2012

13. The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate

The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate Stevenson MD, Lloyd Jones M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of vitamin K 1 versus alendronate, for the treatment of osteoporosis, and it determined the expected value of sample information from a head-to-head clinical trial of the two interventions. Vitamin K 1 might be more cost-effective

NHS Economic Evaluation Database.2011

14. Proton pump inhibitor use and the antifracture efficacy of alendronate

Proton pump inhibitor use and the antifracture efficacy of alendronate 21321287 2011 06 14 2011 09 22 2013 11 21 1538-3679 171 11 2011 Jun 13 Archives of internal medicine Arch. Intern. Med. Proton pump inhibitor use and the antifracture efficacy of alendronate. 998-1004 10.1001/archinternmed.2011.20 Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium (...) , vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures. Population-based, national register-based, open cohort study of 38,088 new alendronate sodium users with a mean duration of follow-up of 3.5 years. We related risk of hip fracture to recent pharmacy records of refill of prescriptions for alendronate. For hip fractures, there was statistically

EvidenceUpdates2011

15. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw.

Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 20950167 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Dec 16;363(25):2473-4. doi: 10.1056/NEJMc1002684. Epub 2010 Oct 16. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. , . Comment in [N Engl J Med. 2011] [N Engl J Med. 2010] PMID: 20950167 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH

NEJM2010

16. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial

Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial 20347511 2010 07 12 2010 07 27 2013 11 21 1523-6838 56 1 2010 Jul American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. 57-68 10.1053/j.ajkd.2009.12.039 Vascular calcification contributes to cardiovascular disease in patients (...) were recruited from a hospital outpatient setting; 50 were treated with study medication. Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly. The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes included superficial femoral artery vascular calcification, arterial compliance, bone mineral density (BMD), renal function, and serum markers of mineral metabolism. At baseline and 12 and 18

EvidenceUpdates2010

17. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis

The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of risedronate compared with generic alendronate for the treatment of postmenopausal women with osteoporosis. The authors concluded that risedronate

NHS Economic Evaluation Database.2010

19. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis 19035979 2009 01 09 2009 06 16 2015 11 19 1365-2036 29 4 2009 Feb 15 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. 424-30 10.1111/j.1365-2036.2008.03899.x Bone loss is often observed in patients (...) with ulcerative colitis, particularly if they require glucocorticoids. To determine whether the bisphosphonate, alendronate, is safe and effective in preserving bone mass compared to the active vitamin D3, alfacalcidol, in ulcerative colitis patients receiving glucocorticoids. Thirty-nine patients with ulcerative colitis and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months. Loss of bone mass was evaluated by bone mineral density

EvidenceUpdates2009

20. Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)

Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial) 18641106 2008 10 09 2008 11 18 2017 02 20 0012-3692 134 4 2008 Oct Chest Chest Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). 794-800 10.1378/chest.08-0608 Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis (...) . A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX; Merck; Whitehouse Station, NJ) in adults with CF and low bone mass. Participants received placebo or alendronate, 70 mg once weekly, for 12 months. All participants received 800 IU of vitamin D and 1,000 mg of calcium daily. Adults with confirmed CF with a bone mineral density (BMD) T score of < - 1.0 were eligible for inclusion. Participants who had undergone

EvidenceUpdates2008